SCHEMBL6691656

SCHEMBL6691656

OCCc1ncnc2c1ncn2C(CO)CCO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 4/20 0.36
ADORA2A P29274 4/20 0.35
ADORA1 P30542 3/20 0.35
ADORA2B P29275 2/20 0.35
PI4KA P42356 1/20 0.35
PI4K2B Q8TCG2 1/20 0.35
PI4K2A Q9BTU6 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
ADA P00813 3/20 0.33
PDE2A O00408 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693460 0.90 AHCY (0.37) AHCYADORA2AADORA1ADORA2BPI4KA
SCHEMBL6691673 0.89 AHCY (0.35) AHCYADORA2AADORA1ADORA2BPI4KA
SCHEMBL6903487 0.81 FGFR1 (0.43) AHCYCYP3A4
SCHEMBL29782858 0.81 FDPS (0.47) AHCYADORA2AADORA1ADORA2BPI4KA
SCHEMBL6899488 0.80 HPRT1 (0.47) AHCYCYP3A4
SCHEMBL6693455 0.79 AHCY (0.36) AHCYADORA2AADORA1ADORA2BPI4KA
SCHEMBL6903378 0.78 CYP1A2 (0.51) CYP1A2
SCHEMBL6693825 0.77 AHCY (0.34) AHCYADORA2AADORA1ADORA2BPI4KA
SCHEMBL12844193 0.75 ADORA2A (0.44) AHCYADORA2AADORA1ADORA2BPI4KA
SCHEMBL6904204 0.75 AHCY (0.34) AHCYADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004106350-A1 NUCLEOSIDE ANALOGS AS VIRAL POLYMERASE INHIBITORS BIOCRYST PHARMACEUTICAL, INC. (US) 2004-12-09 WO claimed
WO-2004106350-A1 NUCLEOSIDE ANALOGS AS VIRAL POLYMERASE INHIBITORS BIOCRYST PHARMACEUTICAL, INC. (US) 2004-12-09 WO disclosed
US-20040014722-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014722-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases NSUN2, POLR2H, NSUN3 AHCY 921/4885ADORA2A 2690/4885ADORA1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.